|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
|
|
|
Dr. Nobu Shimba, CEO and President of Ajinomoto Bio-Pharma Services US, discusses the company’s recent areas of focus as well as current plans for expansions.
|
|
|
Mike Babics, Vice President, Parenteral Services at Alcami, discusses the company’s recent expansions in formulation and analytical development, manufacturing, release testing, and biostorage of clinical and commercial drug products for both solid dosage and parenteral products.
|
|
|
Dr. Joe Dervan says the unique ability of Versamune® to modulate and enhance numerous critical steps required for an effective clinically relevant immune response and to be combined with targeted antigens found on tumor cells offers several exciting opportunities to treat a variety of cancers.
|
|
|
Jim Huang, PhD, and Shaukat Ali, PhD, believe as more hydrophobic or brick dust and/or lipophilic or waxy molecules come out of discovery, amorphous solid dispersions (ASDs) and lipid based self-emulsifying microemulsions, nanoemulsions, liposomes, and nanoparticles are ideal for oral and injectable formulations.
|
|
|
David Lowe, PhD, Justin Hean, PhD, Dave Carter, PhD, and Antonin de Fougerolles, PhD, say EVs exhibit key properties that make them extremely attractive as therapeutics, particularly their safety profile and potential for low immunogenicity. In order to effectively unlock this potential, some key challenges remain, such as the development of EV product manufacture and characterization methodologies and rapid pharmacokinetics.
|
|
|
|
|
|
|
|
|

LATITUDE Pharmaceuticals is a leading-edge CDMO that provides innovative drug formulation development services and GMP manufacturing for early-phase clinical trials to the human and animal health industries. Founded in 2003, we have completed more than 1,000 client projects and have established a reputation for successfully formulating highly insoluble compounds – the most significant cause of drug development failure. Click here for more.
|
|
|
|
|
|
 |
|
Metrion Biosciences Limited and The KCNC1 Foundation recently announced a collaboration to progress a hit identification research project for small molecule modulators of the….
|
|
 |
|
Summit Therapeutics Inc. recently announced a definitive agreement of its partnership with Akeso Inc. to in-license its breakthrough bispecific antibody, ivonescimab…..
|
|
 |
|
Incannex Healthcare Limited recently announced the filing of a provisional patent application directed to the use of IHL-42X for the treatment of Obstructive Sleep Apnoea….
|
|
 |
|
Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonology….
|
|
|
|
|
|
|
|
 |
|
Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….
|
|
 |
|
In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.
|
|
|
|
|
|
|
|
 |
|
Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered mental status and physical impairments find swallowing tablets to be difficult. Orally disintegrating tablets (ODTs), which dissolve completely without chewing …
|
|
 |
|
Achieving good in vivo performance is a key attribute for ensuring safety and efficacy of oral solid dosage (OSD) forms intended for systemic delivery. Yet, new drug targets and mechanisms of action continue to drive drug candidates’ physical properties toward …
|
|
 |
|
The demand for complex, often life-saving drug substances such as monoclonal antibodies, interferons, and peptides is on the rise, creating a greater need for innovative delivery mechanisms to administer these new therapeutics. For a variety of reasons, sub-visible particles can …
|
|
 |
|
ABSTRACT
Lipid nanoparticles (LNPs) are powerful carriers for the delivery of biotherapeutics and active pharmaceutical ingredients (APIs). They are attractive due to their size and biocompatibility, which are important factors when determining the efficacy of an encapsulated API. Particle Works’ …
|
|
|
|
|
Upcoming eNewsletter Features:
January 4 – Capsules
January 11 – Excipients
|
|
|
|
|
|
|
|